All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Change in severity of overall symptoms: intermediate‐term (3 to 4 days) Subjective severity score · patients with common cold
Antihistamines showed no clear difference in change in severity of overall symptoms: intermediate‐term (3 to 4… compared with placebo (high certainty).
1 finding from 1 review
Change in severity of overall symptoms: long‐term (6 to 10 days) Subjective severity score · patients with common cold
Antihistamines showed no clear difference in change in severity of overall symptoms: long‐term (6 to 10 days)… compared with placebo (high certainty).
1 finding from 1 review
Change in severity of overall symptoms: short‐term (1 to 2 days) Subjective severity score · patients with common cold
Sedating antihistamines leads to lower change in severity of overall symptoms: short‐term (1 to 2 days)… compared with placebo (high certainty).
1 finding from 1 review
Change in severity of overall symptoms: long‐term (6 to 10 days) Subjective severity score · patients with common cold
Sedating antihistamines showed no clear difference in change in severity of overall symptoms: long‐term (6 to 10 days)… compared with placebo (high certainty).
1 finding from 1 review
Perinatal mortality (stillbirth ‐ death of fetus prior to birth; neonatal death ‐ death within the first 28 days of birth; or infant death ‐ death after the first 28 days) · pregnant women with a term suspected compromised baby
1 finding from 1 review
Intervention not reported
Number of subjects who develop any adverse event (42 days to 10 months) · adults with asymptomatic bacteriuria
The intervention probably leads to higher number of subjects who develop any adverse event (42 days to 10… (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of subjects with bacteriological cure (42 days to 4 years) · adults with asymptomatic bacteriuria
The intervention probably leads to higher number of subjects with bacteriological cure (42 days to 4 years) (moderate certainty).
1 finding from 1 review
30‐Day mortality · Patients with hip fracture repair
Liberal showed no clear difference in 30‐day mortality compared with restrictive threshold transfusion (low certainty).
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
4 findings from 1 review
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low
Show 1 more finding
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review